How India Exports Nilotinib to the World

As of March 2026, the U.S. Food and Drug Administration (FDA) has approved nilotinib (marketed as Tasigna) for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in both adult and pediatric patients. Notably, on March 22, 2018, the FDA expanded nilotinib's indication to include pediatric patients aged one year and older with newly diagnosed Ph+ CML in the chronic phase, as well as those resistant or intolerant to prior tyrosine kinase inhibitor therapy.

In October 2025, the FDA accepted a New Drug Application (NDA) for XS003, an improved formulation of nilotinib developed by Xspray Pharma. This formulation utilizes the 505(b)(2) regulatory pathway, which allows for the approval of new formulations of previously approved drugs. The Prescription Drug User Fee Act (PDUFA) date for this application is set for June 18, 2026.

Given the specialized nature of nilotinib and its limited number of manufacturers, the presence of 45 active Indian exporters underscores India's significant role in the global supply chain for this medication.

In the European Union, the European Medicines Agency (EMA) has granted marketing authorization for nilotinib for the treatment of Ph+ CML. Similarly, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved nilotinib for the same indication. Manufacturers exporting nilotinib to these markets must comply with the EU's Good Manufacturing Practice (GMP) requirements, ensuring that the product meets stringent quality standards.

As of the 23rd edition of the WHO Model List of Essential Medicines, published in July 2023, nilotinib is not included. (who.int) Consequently, it is not part of the WHO Prequalification Programme. However, nilotinib must adhere to international pharmacopoeia standards, including those set forth by the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure its quality and efficacy.

In India, nilotinib is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for nilotinib, allowing market forces to determine its pricing. For export purposes, Indian manufacturers are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

Nilotinib's primary patents have expired, leading to increased generic competition in various markets. This has resulted in a more competitive pricing environment and expanded access to the medication globally.

In October 2025, the FDA accepted Xspray Pharma's NDA for XS003, an improved formulation of nilotinib, with a PDUFA date set for June 18, 2026.

In April 2025, the World Health Organization (WHO) launched the National Essential Medicines Lists (nEMLs) repository, a centralized digital platform compiling 150 national essential medicines lists from six global regions. This resource aims to enhance access to critical healthcare data, supporting policymakers, healthcare professionals, and researchers. (who.int)

In July 2023, the WHO published the 23rd edition of its Model List of Essential Medicines, which did not include nilotinib. (who.int)

These developments reflect ongoing efforts to improve access to essential medicines and adapt to evolving healthcare needs.

Nilotinib, a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) often relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 70% of India's bulk drug requirements are imported from China, creating significant supply chain vulnerabilities.

Recent disruptions have highlighted the risks associated with this reliance. In October 2025, the U.S. Pharmacopeia reported that 58% of KSMs used for U.S.-approved APIs are solely sourced from a single country, with 41% from China and 16% from India. Such concentration poses a risk of supply interruptions due to geopolitical tensions or regulatory actions.

Our proprietary trade data indicates a high supplier concentration for Nilotinib exports from India. The top five exporters account for 94.2% of the total export value, with JODAS EXPOIM PRIVATE LIMITED alone contributing 88.4%. This dominance suggests a significant single-source risk, as any operational or compliance issues within this leading exporter could disrupt the supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, aiming to boost domestic manufacturing and reduce import dependency. As of July 2025, 48 projects have been approved under this scheme, focusing on the production of critical KSMs, Drug Intermediates (DIs), and APIs. These initiatives are expected to enhance supply chain resilience by diversifying the supplier base and promoting self-reliance.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can lead to delays or increased costs in the transportation of pharmaceutical products. Additionally, ongoing U.S.-China trade tensions have the potential to impact the availability and pricing of KSMs sourced from China, further affecting the production of APIs like Nilotinib.

Regulatory actions also play a role in supply chain stability. In February 2025, the FDA issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practices (cGMP), underscoring the importance of compliance in maintaining uninterrupted supply chains.

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different regions to reduce dependency on a single source.

• Strengthen Compliance Monitoring: Implement robust quality control systems to ensure adherence to cGMP standards, minimizing the risk of regulatory actions.

• Enhance Domestic Production: Leverage government incentives like the PLI Scheme to invest in local manufacturing of critical KSMs and APIs, reducing reliance on imports.

• Develop Contingency Plans: Establish alternative shipping routes and logistics strategies to mitigate potential disruptions in key maritime channels.

• Monitor Geopolitical Developments: Stay informed about international trade policies and geopolitical events that could impact supply chains, allowing for proactive adjustments.

RISK_LEVEL: MEDIUM